Plain-English translation of NCT03921060 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is investigating bone health problems that often develop in people with cystic fibrosis. Researchers want to understand how bone disease develops in CF and test whether a medication called can help strengthen bones and prevent fractures in patients who have already developed bone loss.
People with cystic fibrosis frequently develop weak bones (osteoporosis) as part of their disease, which can lead to fractures and serious complications. This medication is already used to treat bone loss in other conditions, and researchers want to see if it works safely and effectively for CF patients.
You likely qualify if…
You likely don't qualify if…
All participants start with a single visit where you'll have bone density scans, a specialized CT scan, and blood tests to measure your bone health. If you have signs of bone loss and choose to join the medication portion, you'll receive injections every 6 months for up to 5 years and return annually for repeat scans and blood work to see how the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of Texas Southwestern Medical Center
Enrollment target
~100 participants
Started
September 2021
Primary completion
July 2027
Age range
18 Years – 64 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ashley Keller
University of Texas Southwestern Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.